Force phenotyping of airway smooth muscle cells to develop novel asthma therapies
强制气道平滑肌细胞表型分析以开发新型哮喘疗法
基本信息
- 批准号:9452964
- 负责人:
- 金额:$ 23.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2019-01-31
- 项目状态:已结题
- 来源:
- 关键词:ActomyosinAcuteAddressAdrenal Cortex HormonesAdrenergic AgonistsAffectAgonistAnimal ModelAsthmaBiological AssayBronchoconstrictionBronchodilator AgentsCalciumCardiac MyocytesCellsChemicalsClinicalCyclic AMPDataDevelopmentDiseaseDrug ScreeningDrug TargetingEffectivenessEmergency SituationEpigenetic ProcessExtracellular MatrixFDA approvedFibroblastsFutureGenerationsGenomicsHumanImmunofluorescence ImmunologicInflammationInflammation MediatorsInhalationInhalatorsLeadLegal patentLibrariesLinkLungMeasurementMeasuresMethodsMolecularMonitorMuscle ContractionMuscle TonusMuscle relaxation phaseMyosin Light Chain KinaseNatural ProductsOpsoninPathway interactionsPatientsPatternPharmaceutical PreparationsPharmacologyPhenotypePlayPotassium ChannelRelaxationRespiratory physiologyRoleSecond Messenger SystemsSignal TransductionSliceSmooth MuscleSmooth Muscle MyocytesSpecificitySpeedStainsSurfaceSystemTechniquesTestingTimeTissue ModelTissuesVascular Smooth Muscleairway hyperresponsivenessasthma inhalerasthmatic patientbasebeta-2 Adrenergic Receptorscell typeconstrictiondesigndrug discoveryexperimental studyhigh throughput screeninginhibitor/antagonistmacrophagemechanical behaviormolecular phenotypemortalitynew therapeutic targetnovelnovel therapeuticspreventrelease of sequestered calcium ion into cytoplasmrespiratory smooth muscleresponsescreeningtool
项目摘要
ABSTRACT
Asthma is currently treated with drugs that target inflammation (e.g. corticosteroids) and the subsequent
bronchoconstriction (β2 adrenergic receptor agonists) that leads to airway narrowing. Although there are a variety
of mechanisms to inhibit cell force generation and contraction, short- and long-acting bronchodilators operate
through a single mechanism of action, which has negative consequences, since adaptation to a long-acting beta
agonist leads to reduced efficacy of short-acting beta agonist “rescue inhalers.” There is a need for new drugs
that target airway smooth muscle contractility through orthogonal pathways to the beta agonists. However, there
are no current methods to perform high-throughput screens targeting cell force generation. We have developed
a microtechnology-based high-throughput screening approach to characterize cellular force generation at the
single-cell level. We hypothesize that new drugs that interfere with airway smooth muscle cell contractility can
be found that act through separate pathways and lead to new treatment options for asthma patients. In Aim 1
we will conduct a high-throughput screen to identify compounds that relax contraction in airway smooth muscle
cells. We will validate hit compounds in a tissue model - precision cut lung slices. We also anticipate that selective
inhibitors of airway smooth muscle contraction can be developed by counter-screening against other contractile
cells. Our platform allows for combined measurement of immunofluorescence, calcium levels, and contractile
phenotypes for single cells. In Aim 2 we will use this capability to address whether calcium mobilization is
increasing and sufficient to evoke HASM cell shortening by contractile agonists. Molecular inputs that modulate
smooth muscle actomyosin cross-bridge cycling and the strength of contraction remain less understood given
the larger variety of inputs that control smooth muscle tone. Also, we will use this platform to identify new surface
markers associated with hyper-responsive contractile phenotypes highlighting potential key ASM subpopulations
involved in disease. Such surface markers would also assist in designing cell-targeted anti-contractility drugs for
asthma in the future.
摘要
哮喘目前用靶向炎症的药物(例如皮质类固醇)和随后的免疫抑制剂来治疗。
支气管收缩(β2肾上腺素能受体激动剂),导致气道狭窄。虽然有各种各样的
在抑制细胞力产生和收缩的机制中,短效和长效支气管扩张剂起作用
通过一个单一的行动机制,这具有负面影响,因为适应长效β
激动剂导致短效β激动剂“救援吸入器”的功效降低。需要新的药物
其通过与β激动剂正交的途径靶向气道平滑肌收缩。但
目前还没有进行靶向细胞力产生的高通量筛选的方法。我们已经开发
一种基于微技术的高通量筛选方法来表征细胞在
单细胞水平。我们假设,干扰气道平滑肌细胞收缩的新药,
通过不同的途径发挥作用,并为哮喘患者带来新的治疗选择。目标1
我们将进行高通量筛选,以确定放松气道平滑肌收缩的化合物,
细胞我们将在组织模型中验证命中化合物-精确切割肺切片。我们还预计,
气道平滑肌收缩的抑制剂可以通过针对其它收缩剂的反筛选来开发。
细胞我们的平台允许联合测量免疫荧光,钙水平和收缩
单细胞的表型。在目标2中,我们将使用这种能力来解决钙动员是否
增加并足以通过收缩激动剂引起HASM细胞缩短。分子输入调节
平滑肌肌动球蛋白跨桥循环和收缩的强度仍然不太清楚,
控制平滑肌张力的输入的种类更多。此外,我们将使用这个平台来识别新的表面
与高反应性收缩表型相关的标记物,突出潜在的关键ASM亚群
与疾病有关。这种表面标记物也将有助于设计细胞靶向抗收缩药物,
哮喘在未来
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dino Di Carlo其他文献
Dino Di Carlo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dino Di Carlo', 18)}}的其他基金
Hydrogel nanovial technology for single-cell sorting based on extracellular vesicle production
基于细胞外囊泡产生的单细胞分选水凝胶纳米瓶技术
- 批准号:
10411907 - 财政年份:2021
- 资助金额:
$ 23.48万 - 项目类别:
Enhancing the potency of mesenchymal stem cell therapies for kidney diseases using lab-on-a-particle technology
使用粒子实验室技术增强间充质干细胞治疗肾脏疾病的效力
- 批准号:
10373803 - 财政年份:2021
- 资助金额:
$ 23.48万 - 项目类别:
Lab on a particle technology for functional screening of therapeutic cells
用于治疗细胞功能筛选的粒子技术实验室
- 批准号:
10272940 - 财政年份:2021
- 资助金额:
$ 23.48万 - 项目类别:
Hydrogel nanovial technology for single-cell sorting based on extracellular vesicle production
基于细胞外囊泡产生的单细胞分选水凝胶纳米瓶技术
- 批准号:
10193200 - 财政年份:2021
- 资助金额:
$ 23.48万 - 项目类别:
Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)
加州理工学院/加州大学洛杉矶分校个性化治疗诊断工程促进代谢系统 (iTEAM)
- 批准号:
10213026 - 财政年份:2020
- 资助金额:
$ 23.48万 - 项目类别:
Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)
加州理工学院/加州大学洛杉矶分校个性化治疗诊断工程促进代谢系统 (iTEAM)
- 批准号:
10440285 - 财政年份:2020
- 资助金额:
$ 23.48万 - 项目类别:
Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)
加州理工学院/加州大学洛杉矶分校个性化治疗诊断工程促进代谢系统 (iTEAM)
- 批准号:
10683974 - 财政年份:2020
- 资助金额:
$ 23.48万 - 项目类别:
Training the next generation of leaders in biomedical engineering design
培训下一代生物医学工程设计领导者
- 批准号:
10599275 - 财政年份:2019
- 资助金额:
$ 23.48万 - 项目类别:
Training the next generation of leaders in biomedical engineering design
培训下一代生物医学工程设计领导者
- 批准号:
10428473 - 财政年份:2019
- 资助金额:
$ 23.48万 - 项目类别:
Engineering Yeast towards High Titer Production of Monoterpene Indole Alkaloid Natural Products
工程酵母用于高滴度生产单萜吲哚生物碱天然产物
- 批准号:
10735587 - 财政年份:2018
- 资助金额:
$ 23.48万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 23.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 23.48万 - 项目类别:
Operating Grants